Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Rock Springs Capital
AddedFeb 13, 2024
UpdatedJul 16, 2026
Rock Springs Capital

Rock Springs Capital

Operating

Rock Springs Capital: A boutique public equity fund managing diverse interests in key industries.

Location
Baltimore, MD, US
Founded
2013
Firm
Compare
Portfolio
Employees

Investments

Avalyn Pharma
Avalyn Pharma

Total Raised

$272.5M

Rounds

3

Series C$175MSeptember 2023
Genesis Therapeutics
Genesis Therapeutics

Total Raised

$256.1M

Rounds

5

Series B$200MAugust 2023
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Post Ipo Equity$53.6MFebruary 2023
Treeline Biosciences
Treeline Biosciences

Total Raised

$473.3M

Rounds

2

Series A$261.3MOctober 2022
Kymera Therapeutics
Kymera Therapeutics
Public

Total Raised

$879M

Rounds

8

Post Ipo Equity$150MAugust 2022
Delfi Diagnostics
Delfi Diagnostics

Total Raised

$330.5M

Rounds

3

Series B$225MJuly 2022
Series A$100MJanuary 2021
Moma Therapeutics
Moma Therapeutics

Total Raised

$236M

Rounds

2

Series B$150MMay 2022
Simcha Therapeutics
Simcha Therapeutics

Total Raised

$65M

Rounds

2

Series B$40MJanuary 2022
Avenge Bio
Avenge Bio

Total Raised

$45M

Rounds

2

Series A$45MJanuary 2022
Freenome
Freenome

Total Raised

$1.1B

Rounds

8

Series D$300MDecember 2021
Patina
Patina

Total Raised

$57M

Rounds

2

Series A$50MOctober 2021
Honor
Honor
Series E

Total Raised

$695M

Rounds

7

Series E$70MOctober 2021
Whitehawk Therapeutics
Whitehawk Therapeutics
Public

Total Raised

$250.5M

Rounds

4

Post Ipo Equity$155MAugust 2021
Vedanta Biosciences
Vedanta Biosciences

Total Raised

$433.1M

Rounds

15

Series D$68MJuly 2021
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals
Public

Total Raised

$448.5M

Rounds

9

Series C$135MJuly 2021
Imperative Care
Imperative Care

Total Raised

$409M

Rounds

5

Series D$260MJuly 2021
Dmed
Dmed

Total Raised

$214M

Rounds

5

Series C$50MJuly 2021
Kindbody
Kindbody

Total Raised

$306.3M

Rounds

10

Series C$62MJune 2021
Synthekine
Synthekine

Total Raised

$289.5M

Rounds

3

Series B$107.5MJune 2021
Biotheryx
Biotheryx
Public

Total Raised

$134.7M

Rounds

6

Series E$92MMay 2021
Caris Life Sciences
Caris Life Sciences
Public

Total Raised

$1.7B

Rounds

5

Private Equity$830MMay 2021
Personal Genome Diagnostics
Personal Genome Diagnostics

Total Raised

$244.7M

Rounds

6

Series C$103MFebruary 2021
Verve Therapeutics
Verve Therapeutics
Public

Total Raised

$419.3M

Rounds

6

Series B$94MJanuary 2021
Affinivax
Affinivax
Acquired

Total Raised

$377.5M

Rounds

5

Series C$226MJanuary 2021